Read on Twitter
1/ Important milestone in #SARSCoV2 #vaccine development. But need full article (not press release)! https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/
2/ Based on (limited press release) data from @pfizer: interim analysis of 94 confirmed #COVID19 cases out of 38,955 participants who received 2 doses (vaccine & placebo arms combined).
3/ With >90% reported efficacy, this is how the math breaks down:
Risk in vaccine group: 8/19,478 = 0.041%
Risk in placebo group: 86/19,477 = 0.442%
Risk ratio: 0.041% / 0.442% = 0.093
Vaccine efficacy: 1 – risk ratio = 1 – 0.093 = 90.7%
Risk in vaccine group: 8/19,478 = 0.041%
Risk in placebo group: 86/19,477 = 0.442%
Risk ratio: 0.041% / 0.442% = 0.093
Vaccine efficacy: 1 – risk ratio = 1 – 0.093 = 90.7%
4/ Risk difference: 0.442% - 0.041% = 0.40%
Number needed to vaccinate to prevent one case: 1 / risk difference = 1 / 0.0040 = 250
Number needed to vaccinate to prevent one case: 1 / risk difference = 1 / 0.0040 = 250
5/ Trial was conducted in healthy participants at least 12 years of age who had no prior #COVID19 diagnosis. More than 40% from diverse racial-ethnic backgrounds.
7/ Interim data so findings may change. Unpublished study, not peer reviewed.
Still need to see data on:
-Safety and adverse events
-Efficacy in different age/risk groups
-Efficacy against severe outcomes & asymptomatic transmission
-Duration of protection
-Etc.
Still need to see data on:
-Safety and adverse events
-Efficacy in different age/risk groups
-Efficacy against severe outcomes & asymptomatic transmission
-Duration of protection
-Etc.
8/ Full press release available here: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
